Premium
Partnering for Drug Discovery and Development
Author(s) -
Zivin Robert A
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.103.5
Subject(s) - identification (biology) , pharmaceutical industry , drug development , drug discovery , business , drug industry , engineering ethics , data science , medicine , computer science , engineering , drug , pharmacology , biology , bioinformatics , botany
The products of academic research are well represented in today's medicines, representing many Billions in sales and the cutting edge of therapeutics. While some notable examples emerged essentially “completed” from the labs of their inventors, the general case is the identification of a target, a pathway or a chemical biology lead. In these latter cases, many of these advances “wandered in the desert for years” before being “discovered” and incorporated into drugs. The NIH and other organizations have recognized this problem, and have directed significant funding into translational development. With the challenges facing the Pharmaceutical Industry today, it is critical we also develop strategies to rapidly recognize and incorporate these advances and develop the partnerships which will allow us to most effectively address today's unmet medical needs.